At the 2025 annual meeting of the Society for Neuroscience in San Diego this week, Catherine Woolley’s plenary lecture was an ...

Roche AG’s Genentech unit landed another clinical victory with giredestrant that provided a major stock boost for competitor Olema Pharmaceuticals Inc. Made public were positive phase III data from ...

Growth factor specialist Agomab Therapeutics NV is now preparing to move into phase IIb development after delivering positive ...

Aesculap Implant Systems LLC has seen its share of bad news recently, but the company seems to have cleared the legal deck ...

P-glycoprotein (P-gp) is one of several ABC transporters that can pump drugs out of tumor cells and thereby render ...

The health care sector continues to be strong and adaptable despite the challenges over the past year, according to a report ...

GSK plc and the Fleming Initiative have announced six major new research programs to find new ways to slow the progress of ...

Harbour Biomed is stepping up its antibody discovery process by using AI to develop innovative therapeutics. “We have done ...

Medtronic plc posted solid fiscal year second-quarter results led by the cardiovascular business with 9.3% growth. The Affera Sphere-9 pulsed field ablation system tripled the company’s sales in the ...

Top-line results from a midstage study of Vanda Pharmaceuticals Inc.’s tradipitant hit its primary endpoint by preventing the nausea and vomiting that can be caused by the GLP-1 receptor agonist ...

Arrowhead Pharmaceuticals Inc. won U.S. FDA approval of plozasiran in familial chylomicronemia syndrome (FCS), the second drug to gain clearance for use in the rare genetic disease following the late ...

T-knife Therapeutics Inc. has filed a clinical trial application (CTA) to initiate a phase I trial of TK-6302, a PRAME-targeted T-cell receptor (TCR) T-cell therapy in solid tumors. Pending CTA ...